Emani M, Närvä E, Stubb A, et al. The L1TD1 Protein Interactome Reveals the Importance of Post-transcriptional Regulation in Human Pluripotency. Stem Cell Rep. 2015;4(3):519-528.
Närvä E*, Rahkonen N*, Emani M*, et al. RNA-binding protein L1TD1 interacts with LIN28 via RNA and is required for human embryonic stem cell self-renewal and cancer cell proliferation. Stem Cells. 2012;30(3):452-460.
Rahkonen N, Stubb A, Malonzo M, Edelman S, Emani M, et al. Mature Let-7 miRNAs fine tune expression of LIN28B in pluripotent human embryonic stem cells. Stem Cell Res. 2016;17(3):498-503.
Lund RJ, Rahkonen N, Malonzo M, Kauko L, Emani M, et al. RNA Polymerase III Subunit POLR3G Regulates Specific Subsets of PolyA+ and SmallRNA Transcriptomes and Splicing in Human Pluripotent Stem Cells. Stem Cell Rep. 2017;8(5):1442-1454.
Lund RJ, Emani M, et al. Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases. Stem Cell Res. 2013;11(3):1022-1036.
Maheswarareddy Emani, Ph.D.
Maheswarareddy Emani is a research scientist I in the Center for the Development of Therapeutics (CDoT)/Kidney Disease Initiative (KDI) at the Broad Institute of MIT and Harvard, where he works under the direction of Anna Greka. His studies focus on the potential role of induced pluripotent stem (iPS) cells and organoid biology in future kidney care. His goal is to use this cutting-edge stem cell technology to elucidate the molecular mechanisms of epithelial cell injury and repair, and develop therapeutics for rare kidney diseases.
Prior to joining the Broad Institute in September 2017, Emani worked as an R&D research scientist for Orion Corp., Turku, Finland, evaluating iPS cell technology applications suitable for target protein and safety in the context of central nervous system drug discovery. His responsibilities also included development, implementation, and conducting of pharmacological cell and molecular biology assays and setting up physiologically relevant cell models for in vitro screening assays for target proteins. He had previously completed a postdoctoral fellowship at the Turku Center for Biotechnology, Turku, Finland, where he investigated molecular mechanisms underlying a novel RNA binding protein (L1TD1) that regulate human embryonic stem cells’ self-renewal, pluripotency, and reprogramming, and the clinical and prognostic association of human pluripotent stem cell gene expression in cancer.
Emani has been awarded a variety of honors, including the Gold prize for his poster presented at the World Stem Cell Summit 2014, San Antonio, TX; the Elias Tillandz Prize for the best publication in BioCity Turku in 2013; and the prestigious Academy of Finland Postdoctoral Fellowship in 2012. He was nominated by Academy of Finland and was selected to attend the 64th Lindau Nobel Laureate meeting, June 29th to July 4th, 2014, Lindau, Germany.
Emani obtained a Ph.D. in biotechnology at the National Center for Cell Sciences, Pune, India. He also holds a B.Sc. in chemistry, botany, and zoology from Nagarjuna University, Guntur, India, and a M.Sc. in biotechnology from Barkatullah University, Bhopal, India.
Contact Maheswarareddy Emani via email at email@example.com.